Bionik Laboratories Launches Digital Corporate Communication Channels

Aug 26, 2015, 07:35 ET from Bionik Laboratories Corp.

TORONTO, Aug. 26, 2015 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that it has launched a suite of online corporate communication channels to maintain ongoing and direct communication with shareholders and other interested parties. The Company has launched official digital portals on social medial channels including Twitter, LinkedIn, Facebook, Google+ and The Chairman's Blog.

Peter Bloch, CEO of Bionik, stated, "We are committed to the highest standard of excellence in providing timely, clear and transparent communication. We plan to fully utilize our social media channels, along with traditional press releases and required regulatory filings, to quickly and efficiently provide shareholders, the investment community and other key stakeholders with updates on our development advancements for our primary product, ARKE™, a lower body exoskeleton with the potential to transform the future for mobility impaired patients, and our corporate progress as we plan to expand our pipeline with synergistic products and technologies."

The Chairman's Blog is an online communication portal where Bionik Laboratories' executives and leading experts can discuss the Company's efforts to commercialization its proprietary and innovative products to improve overall health, comfort, accessibility, and quality of life for individuals with restricted mobility. The blog also offers an opportunity to address important topics related the medical-robotics industry and trends in mobility rehabilitation.

Links to the new Bionik communication tools are as follow:





The Chairman's Blog:

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. For more information please visit

About Bionik Laboratories
Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company with a focus in developing transformational technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton device that allows paraplegics and as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik successfully raised approximately US$13.1 million which enables the company to rapidly advance a robust product development and growth strategy. For more information, please visit and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

Logo -


SOURCE Bionik Laboratories Corp.